[Role of NO-cGMP-PKG axis in pulmonary arterial hypertension]

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Molecular Signaling

Background:

• The nitric oxide (NO)-cyclic guanosine monophosphate (cGMP)-protein kinase G (PKG) signaling cascade is integral to pulmonary arterial hypertension (PAH) pathogenesis.
• Dysregulation of this pathway leads to pulmonary vascular inflammation, thrombosis, and constriction, driving PAH development.
• Current therapeutic strategies aim to modulate this axis to restore vasodilation and reduce PAH progression.

Purpose of the Study:

• To elucidate the role of the NO-cGMP-PKG pathway in the pathophysiology of pulmonary arterial hypertension (PAH).
• To review established and potential therapeutic modalities targeting the NO-cGMP-PKG pathway for PAH treatment.
• To discuss the clinical applications and patient-specific considerations for agents like PDE5 inhibitors and sGC stimulators.

Main Methods:

• Review of scientific literature on the NO-cGMP-PKG pathway in PAH.
• Analysis of the mechanisms of action for PDE5 inhibitors (e.g., sildenafil, tadalafil) and sGC stimulators (e.g., riociguat).
• Comparison of pharmacokinetic and pharmacodynamic profiles of different therapeutic agents.

Main Results:

• PDE5 inhibitors enhance cGMP levels by preventing its breakdown, promoting smooth muscle relaxation and vasodilation.
• sGC stimulators offer a dual action: sensitizing soluble guanylate cyclase (sGC) to endogenous NO and directly stimulating sGC.
• Individual patient responses to PDE5 inhibitors versus sGC stimulators can differ significantly, indicating personalized treatment needs.

Conclusions:

• Targeting the NO-cGMP-PKG pathway is a key strategy in managing pulmonary arterial hypertension (PAH).
• Both PDE5 inhibitors and sGC stimulators offer distinct mechanisms for modulating this pathway.
• Clinical decision-making requires careful consideration of individual patient characteristics to optimize treatment selection for PAH.